Introduction {#s01}
============

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. There were about 22,440 newly confirmed cases of ovarian cancer and estimated 14,080 EOC-related deaths in the United States in 2017^[@b1]^. More than 70% cases of patients with ovarian cancer are diagnosed in an advanced stage (FIGO stage III or IV) owing to nonspecific symptoms in the early stage and because of the lack of effective screening methods^[@b2]^. The mortality rate among EOC patients remains high and the 5-year overall survival (OS) is only 20%--40% for advanced disease, although some progress has been achieved in EOC treatment^[@b3]^.

MicroRNA (miRNA) and long non-coding RNA (lncRNA) are two important types of non-coding RNA (ncRNA), which play multiple roles in the initiation and progression of various cancers^[@b4],[@b5]^. Some miRNAs and lncRNAs may be useful biomarkers for the early detection and response to treatment of some cancers^[@b6]^. MiRNA is a small non-coding RNA comprising 20--22 nucleotides (nt). It can suppress gene expression by binding with the 3′-untranslated regions (3′-UTRs) of mRNAs and causing mRNA degradation or repression of translation^[@b7]^. LncRNAs are longer than 200 nt in length. They display limited protein-coding potential and have been shown to regulate a variety of cellular processes, such as cell proliferation, apoptosis, cell migration, and tumor metastasis^[@b8]^. The underlying mechanisms of lncRNAs are varied and include acting as competitive endogenous RNAs (ceRNAs) similar to miRNA sponges, chromatin remodeling, and histone-protein modification^[@b9]^.

Hirata et al.^[@b10]^ reported that lncRNA MALAT1 and miR-205 could interact and repress each other, finally acting as crucial regulators for the function of renal cancer. Wan et al.^[@b11]^ also reported that lncRNA PVT1 promoted non-small cell lung cancer cell proliferation through binding to the EZH2 protein and epigenetically regulating LATS2 expression.

The gene encoding plasmacytoma variant translocation I (PVT1) is 1,716 nt in length and it is located in the chr8q24.21 region^[@b12]^. PVT1 has been identified as an oncogene owing to its contribution to the phenotype of multiple cancers^[@b13]-[@b15]^. However, the role of lncRNA PVT1 in ovarian cancer is unclear.

In this study, we evaluated the expression of PVT1 and miR-214 in ovarian cancer and normal ovarian tissues. The relationship of PVT1 and miR-214 expression with the clinicopathologic characteristics and prognosis of EOC patients were analyzed. The analyses were intended to clarify the effects of PVT1 on the malignant behaviors of ovarian cancer cells *in vitro*. The mechanism experiments indicated that PVT1 may recruit EZH2 to the miR-214 promoter and inhibit miR-214 expression. This study will help clarify the role of PVT1 in ovarian cancer progression and its potential as a therapeutic target.

Material and methods {#s02}
====================

Patient collection {#s02.01}
------------------

This study was approved by the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital. Informed consent was obtained from all patients prior to their enrollment in the present study.

A total of 231 patients with EOC, who underwent cytoreductive abdominal surgery between January 2012 and December 2014 were enrolled. Clinical information of all patients was acquired from medical records. The inclusion criteria were: tumor histology originating from epithelial tissue; staging according to the International Federation of Gynecology and Obstetrics (FIGO), including stage I, II, III, and IV; and defined surgical strategies. All patients underwent total hysterectomy with bilateral salpingo-oophorectomy, omentectomy, and appendectomy that were supplemented with partial resection of infiltrated intestine or bowel, peritonectomy, or splenectomy for the purposes of optical cytoreduction. Systemic or sampling lymphadenectomy was performed only in cases when optimal cytoreduction was achieved or in the presence of bulky nodes. Adjuvant therapeutic strategies for all patients included chemotherapy with a platinum-paclitaxel regimen, six standard courses of carboplatin (area under the curve, 5--7.5) and paclitaxel 135--175 mg/m^2^. The adjuvant treatment was modified according to patients\' general status and was used in all cases. Clinical characterizations of patients with ovarian cancer are presented in **[Table 1](#Table1){ref-type="table"}**. Additionally, the control group consisted of 58 normal ovarian tissue samples that were retrieved from peri-menopausal women during hysterectomy with bilateral salpingo-oophorectomy due to benign uterine disease (uterine leiomyoma).

###### 

The characteristics of EOC patients

  Characteristics             Case (*n*, %)
  --------------------------- -------------------------------
  Age at surgery (years)      Media: 51; range: 28--76
  　≤51                       136 (58.9)
  　\>51                      95 (41.1)
  Body mass index (kg/m^2^)   24.18±3.78
  Menopausal status           
  　Yes                       154 (66.7)
  　No                        77 (33.3)
  Pathologic type             
  　Serous                    116 (50.2)
  　Mucous and others\*       115 (49.8)
  Histologic grade            
  　G1--2                     141 (61.0)
  　G3                        90 (39.0)
  FIGO stage\*\*              
  　I--II                     81 (35.1)
  　III--IV                   150 (64.9)
  Lymph nodes metastasis      
  　No                        186 (80.5)
  　Yes                       45 (19.5)
  Residual tumor (cm)         
  　\<1                       187 (81.0)
  　≥ 1                       44 (19.0)
  Ascites volume (mL)         Media: 1000; range: 200--7000
  　≤1000                     157 (68.0)
  　\>1000                    74 (32.0)
  Serum CA125 (U/mL)          Media: 675; range: 23--5400
  　≤675                      140 (60.6)
  　\>675                     91 (39.4)

RNA extraction and real-time quantitative PCR analysis (RT-qPCR) {#s02.02}
----------------------------------------------------------------

Total RNA was extracted from cultured cells or tissues using TRIzol Reagent (Takara Bio, Dalian, China). The reaction mixture (20 μL) containing 1 μg total RNA was reversely transcribed to cDNA using PrimeScript RT-polymerase (Takara Bio). RNA expression levels were measured by RT-qPCR using SYBR Green PCR Master Mix (Takara Bio). U6 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as internal controls. The reactions were performed using a model 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Comparative quantification was determined using the 2^--ΔΔCt^ method. The primers used were PVT1-forward: 5′-TGAGAACTGTCCTTACGTGACC-3′.

PVT1-reverse: 5′-AGAGCACCAAGACTGGCTCT-3′.

MiR-214-forward: 5′-ACA GCA GGC ACA GAC AGG CAG U-3′.

Preparation of cells {#s02.03}
--------------------

Ovarian cancer cell lines (HO8910, SKOV3, ES2, SW626, and A2780) were purchased from the Chinese Academy of Sciences (Shanghai, China). A2780, HO8910, and ES2 cells were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS). SW626 cells were cultured in Leibovitz's L-15 medium (ATCC, Manassas, VA, USA) with 10% FBS. SKOV3 cells were cultured in McCoy's 5A (Gibco, USA) supplemented with 10% FBS (Invitrogen). Human primary cultured ovarian cells (PriCells, Wuhan, China) were gifted by Prof. Xiubao Ren (Tianjin Medical University Cancer Institute and Hospital). The cells were cultured in DMEM (ATCC) supplemented with 10% FBS, penicillin 100 U/mL, and streptomycin 100 mg/mL in humidified air at 37°C in an atmosphere of 5% CO~2~.

Cell transfection {#s02.04}
-----------------

Cells (1×10^5^) were seeded into each well of 6-well plates and incubated for 24 h. Cells were then transfected with PVT1 small interfering RNA (siRNA) oligos, siRNA negative control (si-NC), miR-214 inhibitor, or miR-NC oligos using Lipofectamine 3000 transfection reagent (Invitrogen) according to the manufacturer's instructions.

Cell proliferation assay {#s02.05}
------------------------

SKOV3 cells (1×10^4^ per well) transfected with si-NC or si-PVT1 were cultured in 96-well plates. Proliferation was assessed using the Cell Counting Kit-8 (Dojindo, Kumamoto, Japan) at 1, 2, 3, 4, and 5 days according to the manufacturer's instructions. Absorbance was determined at 450 nm using an Elx800 reader (Bio-Tek Instruments Inc., Winooski, VT, USA).

Wound healing assay {#s02.06}
-------------------

Cells were cultured in McCoy's 5A media containing 5% FBS in 35 mm Petri dishes. Once cells reach 90% confluence media was aspirated and cells were washed twice with PBS and seeded in starvation media of McCoy's 5A and 1% FBS. After overnight culture, media were discarded and cells were washed twice with PBS. Using a 200 μL pipette tip three separate wounds were created across the monolayer cultures perpendicular to the bottom line. The distances of wound were determined at different time intervals (0, 24, and 48 h).

Cell invasion assay {#s02.07}
-------------------

Cell invasion was assessed by Transwell chambers precoated with Matrigel (BD, Franklin Lakes, NJ, USA). After incubation for 48 hours, cells on the upper surface of the Transwell inserts were removed and cells on the lower surface were fixed and then stained with 0.5% crystal violet solution. Cells were counted in five random fields in each well.

Western blot analysis {#s02.08}
---------------------

Proteins from cells were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then immunodetection was performed with standard techniques. Antibodies to E-cadherin, vimentin, β-catenin, Snail, Slug, and β-actin were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Signals were visualized with SuperSignal® West Pico Chemoluminescent Substrate (Pierce, Rockford, IL, USA) by exposure to films.

RNA immunoprecipitation (RIP) {#s02.09}
-----------------------------

The RIP assay was performed using the Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Billerica, MA, USA) following manufacturer's instructions. Total cell lysate was used for immunoprecipitation with EZH2 antibody. Rabbit IgG antibody was used as the control.

Chromatin immunoprecipitation (ChIP) {#s02.10}
------------------------------------

Supernatants were subjected to immunoprecipitation overnight with antibodies against EZH2 (Cell Signaling Technology, Danvers, MA, USA) or with isotype rabbit IgG (Cell Signaling Technology) at 4°C overnight. Chromatin-antibody complexes were isolated by Protein A/G PLUS agarose (Santa Cruz Biotechnology). The crosslinks for the enriched and the input DNA were reversed and the DNA was cleaned by RNase A and proteinase K before phenol/chloroform-purification. For quantification of the enrichment of miR-214 at promoter regions, qRT-PCR was performed using the ABI 7500 Real-Time PCR System (Applied Biosystems). The results are representative of at least three independent experiments.

Statistical analysis {#s02.11}
--------------------

Continuous variables are expressed as the mean ± standard deviation (SD). These variables were analyzed using *t*-test or one-way ANOVA. Chi-squared and Fisher's exact tests were applied in the analysis of categorical variables. The Spearman rank correlation was used to assess the degree of correlation between variables. Survival was determined by the Kaplan-Meier method, and the log-rank test was used to determine significance. Factors that were deemed of potential importance by univariate analysis were included in the multivariate analysis. A *P* \<0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using SPSS software for Windows, version 20.0 (SPSS Inc., Chicago, IL, USA).

Results {#s03}
=======

PVT1 and miR-214 expression in ovarian cancer cell lines and tissues {#s03.01}
--------------------------------------------------------------------

PVT1 and miR-214 were detected by qRT-PCR assay in tissues obtained from 231 EOC patients and 58 normal ovarian tissues. The results showed that the expression of PVT1 was significantly higher in tumor tissues than in normal ovarian tissues (**[Figure 1A](#Figure1){ref-type="fig"}**, *P*\<0.05). However, the expression of miR-214 was significantly lower in tumor tissues than in normal ovarian tissues (**[Figure 1B](#Figure1){ref-type="fig"}**, *P*\<0.05). The expression of PVT1 was up-regulated in ovarian cancer cell lines compared to that in human primary ovarian cells (*P*\<0.05) and PVT1 expression was the highest in SKOVs3 cells (**[Figure 1C](#Figure1){ref-type="fig"}**). On the other hand, the expression of miR-214 was significantly down-regulated in the ovarian cancer cell lines compared to that in human primary ovarian cells (*P*\<0.05) and miR-214 expression was the lowest in SKOV3 cells (**[Figure 1D](#Figure1){ref-type="fig"}**). Thus, SKOV3 cells were chosen to perform the subsequent *in vitro* functional assays.

![PVT1 and miR-214 expression in ovarian cancer cell lines and tissues. (A) The expression of PVT1 was significantly higher in tumor tissues compared to normal ovarian tissues. (B) The expression of miR-214 was obviously lower in tumor tissues compared to normal ovarian tissues. (C) The expression of PVT1 was up-regulated in ovarian cancer cell lines (SKOV3, HO8910, ES2, A2780, and SW626) compared to human primary ovarian cells and PVT1 expression was the highest in SKOV3 cells. (D) The expression of miR-214 was down-regulated in ovarian cancer cell lines (SKOV3, HO8910, ES2, A2780, and SW626) compared to human primary ovarian cells and miR-214 expression was the lowest in SKOV3 cells (\**P*\<0.05).](cbm-15-3-238-1){#Figure1}

Relationship of PVT1 and miR-214 expression with clinicopathologic features of EOC patients {#s03.02}
-------------------------------------------------------------------------------------------

EOC patients were assigned into two groups (high PVT1 expression *vs* low PVT1, and high miR-214 expression *vs* low miR-214 expression) according to the median expression of PVT1 and miR-214 (**[Table 2](#Table2){ref-type="table"}**). The results indicated that the higher PVT1 expression was associated with advanced FIGO stage (*P*\<0.05). Lower miR-214 expression was related to EOC with a lower differentiated and advanced stage (both*P*\<0.001). In general, higher expression of PVT1 and lower expression of miR-214 indicated more malignant clinical behavior of EOC.

###### 

Correlation of PVT1 and miR-214 expression with clinicopathologic characteristics of EOC patients

  Characteristics         *n*   PVT1 expression, *n*   *P*   MiR-214 expression, *n*   *P*        
  ----------------------- ----- ---------------------- ----- ------------------------- ----- ---- ---------
  Age (years)                                                0.679                                0.885
  　≤51                   136   61                     75                              76    60   
  　\>51                  95    40                     55                              54    41   
  Menopause                                                  0.302                                0.453
  　Yes                   154   71                     83                              84    70   
  　No                    77    30                     47                              46    31   
  Pathologic type                                            0.940                                0.129
  　Serous                116   51                     65                              71    45   
  　Mucous and others\*   115   50                     65                              59    56   
  Histologic grade                                           0.924                                \<0.001
  　G1--2                 141   62                     79                              63    78   
  　G3                    90    39                     51                              67    23   
  FIGO stage                                                 \<0.001                              \<0.001
  　I--II                 81    53                     28                              29    52   
  　III--IV               150   48                     102                             101   49   
  LN metastasis                                              0.436                                0.266
  　No                    186   79                     107                             108   78   
  　Yes                   45    22                     23                              22    23   
  Residual tumor (cm)                                        0.552                                0.204
  　\<1                   187   80                     107                             109   78   
  　≥ 1                   44    21                     23                              21    23   
  Ascites volume (mL)                                        0.216                                0.232
  　≤1000                 157   73                     84                              83    72   
  　\>1000                74    28                     46                              47    29   
  Serum CA125 (U/mL)                                         0.548                                0.831
  　≤675                  140   59                     81                              78    62   
  　\>675                 91    42                     49                              52    39   

Correlation between PVT1 and miR-214 expression in EOC {#s03.03}
------------------------------------------------------

Among 101 EOC tissues with low PVT1 expression, 49 cases (48.5%) displayed low expression of miR-214. The remaining 51.5% displayed high expression of miR-214. Of 130 EOC tissues with high PVT1 expression, 81 (62.3%) displayed low expression of miR-214. Thus, there was a negative relationship between PVT1 and miR-214 expression (correlation coefficient=0.137, *P*\<0.05;**[Table 3](#Table3){ref-type="table"}**).

###### 

The relationship between PVT1 and miR-214 expression in EOC tissues

                       PVT1 expression, *n* (%)   Total cases   *ρ*   *P*     
  -------------------- -------------------------- ------------- ----- ------- -------
  MiR-214 expression                                                  0.137   0.036
  　Low                49 (48.5)                  81 (62.3)     130           
  　High               52 (51.5)                  49 (37.7)     101           
  Total cases          101                        130           231           

Survival analysis of PVT1 and miR-214 expression among EOC patients {#s03.04}
-------------------------------------------------------------------

The results indicated the shorter median progression-free survival (PFS) and OS were associated with lymph node metastasis, advanced stage, high PVT1 expression, and lower miR-214 expression by univariate analysis (*P*\<0.05;**[Table 3](#Table3){ref-type="table"}**). Moreover, EOC patients with poorly differentiated tumors (G~3~) had a shorter median PFS (*P*=0.025; **[Table 4](#Table4){ref-type="table"}**).

###### 

Univariate and multivariate survival analyses of the prognostic factors for overall and disease-free survival in EOC patients

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable                *n*   Progression-free survival             Overall survival                                                                        
  ----------------------- ----- --------------------------- --------- ------------------ ------- ---------- --------- -- ---- --------- -- ------- ---------- ---------
  Age (years)                                               0.621                        NA      NA         NA                0.676        NA      NA         NA

  　≤51                   136   30                                                                                       42                                   

  　\>51                  95    31                                                                                       44                                   

  Menopause                                                 0.373                        NA      NA         NA                0.488        NA      NA         NA

  　Yes                   154   30                                                                                       43                                   

  　No                    77    32                                                                                       44                                   

  Pathologic type                                           0.978                        NA      NA         NA                0.849        NA      NA         NA

  　Serous                116   30                                                                                       41                                   

  　Mucous and others\*   115   31                                                                                       44                                   

  Histologic grade                                          0.025                        1.083   0.802--\   0.604             0.114        NA      NA         NA
                                                                                                 1.462                                                        

  　G1--2                 141   42                                                                                       44                                   

  　G3                    90    34                                                                                       40                                   

  FIGO stage                                                \<0.001                      2.265   1.632--\   \<0.001           \<0.001      1.994   1.423--\   \<0.001
                                                                                                 3.144                                             2.792      

  　I--II                 81    44                                                                                       58                                   

  　III --IV              150   24                                                                                       39                                   

  LN metastasis                                             0.019                        1.366   0.958--\   0.085             0.035        1.274   0.887--\   0.190
                                                                                                 1.947                                             1.829      

  　No                    186   31                                                                                       43                                   

  　Yes                   45    24                                                                                       41                                   

  Residual tumor (cm)                                       0.277                        NA      NA         NA                0.806        NA      NA         NA

  　\<1                   187   31                                                                                       43                                   

  　≥ 1                   44    30                                                                                       41                                   

  Ascites volume (mL)                                       0.237                                                             0.403        NA      NA         NA

  　≤1000                 157   40                                                       NA      NA         NA           55                                   

  　\>1000                74    36                                                                                       58                                   

  Serum CA125 (U/mL)                                        0.753                        NA      NA         NA                0.991        NA      NA         NA

  　≤675                  140   36                                                                                       55                                   

  　\>675                 91    39                                                                                       55                                   

  PVT1 expression                                           0.016                        1.111   0.819--\   0.498             0.020        1.153   0.842--\   0.375
                                                                                                 1.506                                             1.579      

  　Low                   101   34                                                                                       51                                   

  　High                  130   28                                                                                       40                                   

  MiR-214 expression                                        0.021                        1.246   0.925--\   0.148             0.034        1.193   0.880--\   0.256
                                                                                                 1.680                                             1.616      

  　Low                   130   28                                                                                       41                                   

  　High                  101   31                                                                                       44                                   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

Variables that were significant in the univariate analysis were examined by multivariate analysis. We found the FIGO stage was the independent factor for evaluation of PFS and OS in the Cox proportional hazard model (*P*\<0.001;**[Table 4](#Table4){ref-type="table"}**). EOC patients with high PVT1 expression and low miR-214 expression displayed shorter PFS and OS than patients with low PVT1 expression and high miR-214 expression, respectively (**[Figure 2A](#Figure2){ref-type="fig"}**-**[D](#Figure2){ref-type="fig"}**).

![Kaplan--Meier analysis for PFS and OS of EOC. (A) High PVT1 expression demonstrated the shorter median of PFS compared to low PVT1 expression (28 *vs*. 34 months, *P*=0.016). (B) High PVT1 expression demonstrated the shorter median of OS compared to low PVT1 expression (40 *vs*. 51 months, *P*=0.020). (C) Low miR-214 expression demonstrated the shorter median of PFS compared to high miR-214 expression (28 *vs*. 31 months, *P*=0.021). (D) Low miR-214 expression demonstrated the shorter median of OS compared to high miR-214 expression (41 *vs*. 44 months, *P*=0.034).](cbm-15-3-238-2){#Figure2}

Effect of PVT1 knockdown on ovarian cancer cell proliferation, migration, and invasion {#s03.05}
--------------------------------------------------------------------------------------

To investigate the functional role of PVT1 in ovarian cancer, si-PVT1 was transfected into SKOV3 cells. Satisfactory repression efficiency was achieved at 48 after transfection (**[Figure 3A](#Figure3){ref-type="fig"}**). Then, CCK-8 and wound healing assays showed that knockdown of PVT1 inhibited SKOV3 cell proliferation and migration, respectively (**[Figure 3B](#Figure3){ref-type="fig"}** and **[3D](#Figure3){ref-type="fig"}**). Additionally, an invasion assay showed that knockdown of PVT1 dramatically decreased SKOV3 cell invasion (**[Figure 3C](#Figure3){ref-type="fig"}**). Furthermore, we detected epithelial-mesenchymal transition (EMT) markers and found that mesenchymal marker proteins (vimentin and β-catenin) and dedicated EMT transcription factors (Snail and Slug) were down-regulated in SKOV3 cells with PVT1-knockdown, while the epithelial marker E-cadherin was up-regulated (**[Figure 3E](#Figure3){ref-type="fig"}**).

![Knockdown of PVT1 inhibits ovarian cancer cell proliferation, migration, and invasion. (A) Satisfactory repressing efficiency was achieved at 48 h after transfection. (B) CCK-8 assay showed that knockdown of PVT1 inhibited SKOV3 cell proliferation. (C) Invasion assay showed that knockdown of PVT1 dramatically decreased SKOV3 cell invasion. (D) Wound healing assay showed that knockdown of PVT1 inhibited SKOV3 cell migration. (E) Mesenchymal marker proteins (Vimentin and β-catenin) and EMT-mediating transcription factor (Snail and Slug) were down-regulated in SKOV3 cells with PVT1-knockdown, while epithelial marker E-cadherin was up-regulated (\**P*\<0.05).](cbm-15-3-238-3){#Figure3}

PVT1 inhibits miR-214 expression by interacting with EZH2 in ovarian cancer cells {#s03.06}
---------------------------------------------------------------------------------

To further detect whether PVT1 affects gene expression by recruiting EZH2 to its target genes, the RIP assay was conducted using an antibody against EZH2 in SKOV3 cells. The results showed that PVT1 was enriched in the anti-EZH2 RIP fraction compared to that in the anti-IgG fraction in SKOV3 cells (**[Figure 4A](#Figure4){ref-type="fig"}**). Therefore, these results indicated PVT1 was significantly associated with EZH2. Furthermore, PVT1 knock-down led to the up-regulation of miR-214 in SKOV3 cells (**[Figure 4B](#Figure4){ref-type="fig"}**). Additionally, miR-214 was significantly up-regulated after si-EZH2 was transfected into SKOV3 cells (**[Figure 4C](#Figure4){ref-type="fig"}**). To evaluate whether PVT1 represses miR-214 mRNA expression by recruiting EZH2 to the promoter of miR-214, the ChIP assay was performed with SKOV3 cells. The results showed that PVT1 silencing decreased the binding ability between EZH2 and miR-214 promoter compared to the IgG group (**[Figure 4D](#Figure4){ref-type="fig"}**).

![PVT1 inhibits the miR-214 expression by interacting with EZH2 in ovarian cancer cells. (A) PVT1 was enriched in the anti-EZH2 RIP fraction compared to the anti-IgG fraction in SKOV3 cells. (B) After PVT1 was knocked down, miR-214 was up-regulated in SKOV3 cells. (C) MiR-214 was significantly up-regulated after si-EZH2 was transfected into SKOV3 cells. (D) Chromatin immunoprecipitation (ChIP) method proved that PVT1 silencing decreased the binding ability between EZH2 and miR-214 promoter compared to IgG group. (E) The expression of miR-214 was decreased in PVT1 repressing SKOV3 cells using miR-214 inhibitor. (F) CCK-8 assay showed that si-PVT1 inhibited the proliferation of SKOV3 cells and miR-214 inhibitor could counteract the si-PVT1 inhibiting effect of SKOV3 cells. (G) Wound healing assay showed that si-PVT1 inhibited the migration of SKOV3 cells. However, miR-214 inhibitor could counteract the si-PVT1 inhibiting effect in SKOV3 cells. (H) Invasion assay showed that si-PVT1 inhibited the invasion of SKOV3 cells. However, miR-214 inhibitor could counteract the si-PVT1 inhibiting effect in SKOV3 cells (\**P*\<0.05).](cbm-15-3-238-4){#Figure4}

To dissect the effect of miR-214 binding to PVT1 on ovarian cancer progression, the expression of miR-214 was decreased in PVT1 repressing SKOV3 cells using miR-214 inhibitor (**[Figure 4E](#Figure4){ref-type="fig"}**). By using the CCK-8 assay, we found that si-PVT1 inhibited the proliferation of SKOV3 cells and that the miR-214 inhibitor could counteract the si-PVT1 inhibiting effect in SKOV3 cells (**[Figure 4F](#Figure4){ref-type="fig"}**). Wound healing assay and the invasion assay showed that si-PVT1 inhibited the migration and invasion of SKOV3 cells (**[Figure 4G](#Figure4){ref-type="fig"}** and **[4H](#Figure4){ref-type="fig"}**). However, miR-214 inhibitor could counteract the si-PVT1 inhibiting effect in SKOV3 cells (**[Figure 4G](#Figure4){ref-type="fig"}** and **[4H](#Figure4){ref-type="fig"}**). These results demonstrated that PVT1 promotes the progression of ovarian cancer by silencing miR-214. The potential mechanism was likely that PVT1 prompted the binding of EZH2 to the miR-214 promoter, with the resulting inhibition of miR-214 expression.

Discussion {#s04}
==========

LncRNAs are transcripts of more than 200 nt in length with limited protein encoding functions. They have been implicated in the molecular mechanisms of carcinogenesis^[@b16]^. As regulators of genetic information flow that interact with the epigenetic, transcriptional, and posttranscriptional pathways, lncRNAs promote tumor formation, progression, and metastasis in many human malignancies^[@b17]^. MiRNAs are another vital class of small ncRNAs, which are involved in some pathological progresses, especially cancer^[@b18]^. The model of miRNA action involves binding to target mRNAs via sequence complementarities, which results in mRNA destabilization and translation inhibition^[@b19]^.

In this study, we found that the expression of PVT1 was significantly higher in tumor tissues than in normal ovarian tissues. On the contrary, the expression of miR-214 was obviously lower in tumor tissues than in normal ovarian tissues. Similar results were also found in ovarian cancer cell lines *in vitro*. Moreover, higher PVT1 expression was associated with advanced FIGO stage. Lower miR-214 expression was related to EOC featuring lower tumor differentiation and an advanced stage. In general, higher expression of PVT1 and lower expression of miR-214 indicated a clinically more malignant EOC, with a negative relationship between the expression of PVT1 and miR-214 in EOC tissues. Importantly, univariate survival analysis revealed that EOC patients with high PVT1 expression and low miR-214 expression were more likely to have shorter PFS and OS than those with low PVT1 expression and high miR-214 expression. Our results were quite consistent with those of previous studies. Zhang et al.^[@b20]^ reported that PVT1 was up-regulated in cervical cancer tissues. Enhanced expression of PVT1 was associated with larger tumor size, advanced stage, and poor prognosis of patients with cervical cancer. Kong et al.^[@b14]^ indicated the overexpression of PVT1 was suggestive of a poor prognosis of gastric cancer and promoted cell proliferation through epigenetic regulation of p15 and p16. Similarly, Takahashi et al.^[@b21]^ demonstrated that amplification of PVT1 is involved in poor prognosis via apoptosis inhibition in colorectal cancer.

As for miR-214, accumulating evidence suggests that miR-214 participation in carcinogenesis is common, although the specific role of miR-214 can vary depending on the type of cancer. Yang et al.^[@b22]^ showed that miR-214 was up-regulated and induced cisplatin resistance in ovarian cancer cells. In both human osteosarcoma^[@b23]^ and nasopharyngeal carcinoma^[@b24]^, miR-214 expression was up-regulated and it was elucidated as an oncogene. However, down-regulation of miR-214 was observed in hepatocellular cancer tissues, indicating an anti-oncogene function of miR-214^[@b25]^.

Recently, lncRNAs were reported to be capable of binding with miRNAs and can prevent them from interacting with their target mRNAs. LncRNAs belong to ceRNAs and their roles and functions in cancer have been described^[@b26]^. Recently, Mitra et al.^[@b27]^ reported that MEG3 can influence the expression of STAT3 by altering miR-21 expression in ovarian carcinoma. In addition, there was another association between lncRNAs and miRNAs, in which lncRNAs are a precursor RNAs for miRNAs. For example, H19 is a precursor RNA for miR-675^[@b28]^. MiR-214 functions as a tumor suppressor in breast cancer^[@b29]^ and colon cancer^[@b30]^, and as an oncogene by targeting PTEN in gastric cancer^[@b31]^, targeting β-catenin in esophageal cancer^[@b32]^, and promoting EMT and metastasis in lung cancer by targeting the suppressor-of--fused protein^[@b33]^. Additionally, miR-214 can interact with lncRNA DANCR, which is overexpressed in stem-like hepatocellular carcinoma (HCC) cells, and serves as a prognostic biomarker for HCC patients^[@b34]^. MiR-214 has also been identified as an oncogene in nasopharyngeal carcinoma by reversing the inhibitory effect of LINC0086 on carcinoma cell growth^[@b35]^.

In this study, in order to further investigate the functional role of PVT1 in ovarian cancer, the PVT1 expression was knocked down in SKOV3 cells. The results showed that knockdown of PVT1 inhibited SKOV3 cell proliferation, migration, and invasion. The mechanism experiments demonstrated that PVT1-mediated progression of ovarian cancer involved cell progression through silencing miR-214 in cancer cells. The likely potential mechanism was the PVT1-mediated binding of EZH2 to the miR-214 promoter and the subsequent inhibition of miR-214 expression. EZH2 is a histone methyltransferase that induces histone H3 lysine 27 trimethylation (H3K27me3) in specific gene loci and then inhibits gene expression. Consistent with our results, Gou et al.^[@b12]^ reported that PVT1 inhibited the miR-214 expression via binding to EZH2 and recruit EZH2 to the promoter of miR-214 promoter in HCC cells.

EMT has been proven to be an important early event of tumor cell metastatic dissemination, in which cells are endowed with a more motile and invasive potential^[@b36]^. Mesenchymal marker proteins (vimentin and β-catenin) and EMT-mediating transcription factors (Snail and Slug) were down-regulated in SKOV3 cells with PVT1-knockdown, while the epithelial marker E-cadherin was up-regulated in our study, which indicates that PVT1 promotes ovarian cancer progression and may be also involved in the regulation of the EMT process. Yuan et al.^[@b37]^ reported that lncRNA-ATB acted as a ceRNA and shared miR-200 response elements with ZEB1, which induced EMT in HCC. Shen et al.^[@b36]^ also demonstrated that lncRNA-PE was upregulated in HCC cell lines and tissues, and acted as a key regulator of the miR-200-EMT pathway to promote HCC progression. The transcriptional factors ZEB1 and ZEB2 induce EMT by repressing the expression of E-cadherin and promote cancer cell proliferation, invasion, and metastasis^[@b7]^. The accurate mechanism of PVT1 in the progression of EMT requires further study.

In conclusion, we demonstrate that PVT1 is up-regulated in ovarian cancer. Higher PVT1 expression is associated with advanced FIGO stage and with poor prognosis in ovarian cancer patients. Ovarian cancer cell proliferation, migration, and invasion are inhibited after knockdown of PVT1 expression *in vitro*. Furthermore, PVT1-mediated promotion of ovarian cancer progression may be involved in the regulation of the EMT process, and PVT1 interacts with EZH2 to repress miR-214 expression in ovarian cancer cells. Our findings facilitate the understanding of PVT1 function in the tumorigenesis of ovarian cancer and indicate that further studies are required to investigate the mechanisms of PVT1/miR-214 in various types of ovarian cancer. Finally, the data point the way towards the development of a novel diagnostic marker and therapeutic target for ovarian cancer.
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